Belgium-based UCB selected Gwinnett County, Georgia, as the location for its new U.S. biologics manufacturing facility. The campus will use a digital-first approach by leveraging AI, robotics, and ...

The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. The North American headquarters of Belgian ...

FILE - The North American headquarters of Belgian pharmaceutical company UCB is seen, Nov. 10, 2014, in Smyrna, Ga. (Paul Abell/AP Images for UCB, Inc., File) (Paul Abell) ATLANTA – Belgian ...

UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first plant in the U.S. for the Belgium-based company and will produce ...

A rendering of the new UCB campus at Rowen in Gwinnett County. The company says it will take Credit: UCB The company said last June that it would soon build a U.S. biologics factory with a $5 billion ...

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...

Belgian drugmaker UCB has entered into an agreement to licence Antengene's (6996.HK), opens new tab experimental autoimmune disease therapy ATG-201 and associated ‌technology, paying $60 million up ...

SAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Citizen Health today announced a new strategic partnership with UCB, a global biopharmaceutical leader in neurological and autoimmune ...

The energy that powers cells of the human body comes from tiny cellular components called mitochondria. Just as a draining battery makes it difficult to operate an electronic device, mitochondrial ...

LinkedIn support accidentally revealed its algorithm: it tracks "viewer tolerance," reducing visibility for authors whose posts are consistently ignored. To succeed, diversify content types weekly, ...